ISIS 2503 in Treating Patients With Metastatic and/or Locally Recurrent Colorectal Cancer
Ontology highlight
ABSTRACT: RATIONALE: ISIS 2503 may kill cancer cells by inhibiting a gene that promotes the development and growth of cancer.
PURPOSE: Phase II trial to study the effectiveness of ISIS 2503 in treating patients who have metastatic and/or locally recurrent colorectal cancer.
DISEASE(S): Colorectal Cancer,Colorectal Neoplasms
PROVIDER: 2003607 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA